Posted by Michael Wonder on 30 Apr 2025
Q32 Bio announces FDA fast track designation granted to bempikibart (ADX-914) for the treatment of alopecia areata
30 April 2025 - Q32 Bio today announced that the US FDA has granted fast track designation to Q32 Bio's bempikibart (ADX-914) for the treatment of alopecia areata.
Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signalling that is in development for the treatment of alopecia areata and currently being evaluated in a Phase 2 program.
